CD4 and rheumatoid arthritis: Strengths of this study are that all patients included were untreated and had newly diagnosed RA, which eliminates differences in disease duration and treatment history, and that we compare the effects of three different bDMARDs prospectively on circulating CD4+ T cell subset proportions in a randomized clinical trial.